

Gnd
 al
 culturing a bacterial strain according to claim 17 with a substrate under conditions
 suitable to produce a medicinal product.

22. A method according to claim 21, wherein the medicinal product is a vaccine.

REMARKS

Applicants respectfully submit that no prohibited new matter has been introduced
 by this Preliminary Amendment and that claims 11-22 are drawn to the same invention as
 claims 1-10 of International Application PCT/FR99/03270. The changes to the claims
 represent changes in formalities so as to bring the claims into compliance with the rules
 of practice in the United States, such as "use" claims (original claims 7-10) have been re-
 written as method claims; standard claim terminology has been adopted i.e.,
 "characterized in that" has been replaced by comprising (see original claims 1 and 6) and
 to adopt standard grammatical constructions (see all the original claims). The limitation
 with regard to genome size present in original claim 1 has been removed from claim 11
 and placed in dependent claim 12. These changes do not narrow the scope of the claimed
 subject matter present and examined in the corresponding International Application.

Respectfully submitted,

MORGAN, LEWIS & BOCKIUS LLP

Dated: June 27, 2001

By: Lawrence J. Carroll

Lawrence J. Carroll, Ph.D.
 Registration No. 40,940

Customer No. 009629

MORGAN, LEWIS & BOCKIUS LLP

1800 M Street, NW

Washington, D.C. 20036

Tel: 202-467-7000; Fax: 202-467-7258